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2) the absence of any other pathogen; 
and 3) wound healing during appropri-
ate, long-term antimicrobial drug treat-
ment. However, the source of infection 
remained unknown. The patient had 
a tattoo on the skin ﬂ  ap used for the 
breast reconstruction, and ink has been 
shown to be a source for rapidly grow-
ing mycobacteria other than M. con-
ceptionense ( 6). However, the tattoo 
was 5 years old and clinically safe.
Recent reports have identiﬁ  ed 12 
M. conceptionense isolates from wa-
ter collected in a cooling tower (7) 
and 9 isolates from various freshwater 
ﬁ  sh species (8). The type strain of M. 
conceptionense had been isolated af-
ter prolonged exposure of the patient 
to fresh water (4). These observations 
suggest that water is a potential source 
for M. conceptionense. In this patient, 
use of contaminated aqueous solutions 
or inadequately rinsed surgical equip-
ment (9) was unlikely the source of in-
fection because further investigations 
indicated proper use of sterilized, non-
reusable surgical equipment. At home, 
the patient used well water, but results 
of tests used to detect M. conception-
ense by culture and the presence of 
the rpoB gene in well water remained 
negative.
Because M. conceptionense is an 
emerging pathogen with only 2 re-
ported cases of infection (4,10), the 
optimal treatment is unknown (Table). 
Current recommendations for breast 
implant infection from M. fortuitum 
include 6 months of appropriate anti-
microbial drug treatment in addition to 
implant removal because surgery alone 
yields relapse within 4–6 weeks (2,3). 
Increased worldwide use of breast im-
plants is likely to increase the number 
of  M. conceptionense infections and 
will raise questions about the optimal 
management of these infections. 
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Rapid Diagnostic 
Tests and Severity 
of Illness in 
Pandemic (H1N1) 
2009, Taiwan 
To the Editor: The recent pan-
demic (H1N1) 2009 (1) demonstrates 
the need for more sensitive rapid di-
agnostic tests (RDTs) to distinguish 
between inﬂ  uenza and other respira-
tory viruses, enhance inﬂ  uenza  sur-
veillance, and institute early antiviral 
therapy for patients who are severely 
ill or at high risk (2). In anticipation of 
the global spread of pandemic (H1N1) 
2009, on August 15, 2009, the gov-
ernment of Taiwan began perform-
ing RDTs at clinics and hospitals for 
patients with inﬂ  uenza-like  illness. 
This initiative was based in part on the 
notion that patients with higher viral 
loads would be more likely to have a 
positive RDT result and more severe 
disease. We report that RDTs may 
have paradoxically lower sensitiv-
ity for pandemic (H1N1) 2009 virus 
for patients with respiratory failure 
requiring mechanical ventilation, ex-
tracorporeal membrane oxygenation 
(ECMO) or both than for those with-
out respiratory failure.
National Taiwan University Hos-
pital is a 2,200-bed teaching hospi-
tal in Taiwan. This hospital provides 
primary and tertiary care and ECMO. 
All patients admitted with presumed 
severe inﬂ   uenza were immediately 
treated with oseltamivir during the 
2009 pandemic. From July 25 through 
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December 28, 2009, we studied 20 
patients with conﬁ  rmed disease and 3 
adult patients with suspected disease 
who met the US Centers for Disease 
Control and Prevention case deﬁ  ni-
tions for pandemic (H1N1) 2009 (3).
An RDT (QuickVue A+B; Quidel, 
San Diego, CA, USA) was performed 
by using nasopharyngeal swab speci-
mens. Genetic material speciﬁ  c  for 
pandemic (H1N1) 2009 viruses was 
detected in nasopharygeal or throat 
swab specimens by real-time reverse 
transcription–PCR at the Centers for 
Disease Control and Prevention, Tai-
wan (4). Demographic and clinical 
characteristics of the 23 patients are 
shown in the Table.
Severity of illness was assessed 
within 24 hours of admission by de-
termining the Acute Physiology and 
Chronic Health Evaluation II score 
(5). The highest Sequential Organ 
Failure Assessment score was calcu-
lated to predict outcome of critically 
ill patients during their stay in the 
intensive care unit (6). The Student 
t test was used to assess continuous 
variables, and χ2 or Fisher exact tests 
were used to assess discrete variables. 
A p value <0.05 was considered sig-
niﬁ   cant. Statistical analyses were 
performed by using SAS software 
version 9.1 (SAS Institute, Cary, NC, 
USA).
There were no differences in age, 
sex, body mass index, underlying 
diseases, or occurrence of secondary 
bacterial infection between patients 
who received mechanical ventilation 
(n = 15) and those who did not (n = 
8). There were no signiﬁ  cant differ-
ences between the 2 groups in the 
median number of days from onset 
of illness to access to medical care. 
Patients receiving mechanical venti-
lation had higher severity-of-illness 
scores and longer times in the inten-
sive care unit and the hospital. Sensi-
tivity of the RDT was 100% for pa-
tients who did not receive mechanical 
ventilation and 26.7% for those who 
did (p<0.0001).
Median age of the 8 patients who 
received ECMO was 31 years. Only 
3 patients had underlying diseases. 
RDT results were positive for only 1 
of these patients. Five patients were 
tested by RDT more than one time 
before transfer or hospitalization. The 
interval from onset of illness to the 
ﬁ  rst RDT was 1 d for 1 patient, 2 d 
for 4 patients, 3 d for 2 patients, and 
6 d for 1 patient. Failure of the RDT 
to detect inﬂ  uenza was associated with 
a delay of >5 d in instituting antiviral 
therapy for 6 of 8 patients who re-
ceived ECMO. However, ECMO was 
stopped for 7 patients who were dis-
charged from hospital after a median 
duration of 23 d (interquartile range 
11.5–54 d) of ECMO.
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Table. Characteristics of 23 hospitalized patients with confirmed (n = 20) and suspected (n = 3) pandemic (H1N1) 2009, Taiwan* 
Characteristic 
No mechanical 
ventilation (n = 8) 
Mechanical ventilation 
Non-ECMO (n = 7)  ECMO (n = 8) 
Age, y      
  Mean ± SD  39.9 ± 12.8  44.4 ± 19.5  34.6 ± 15.0 
 >65, no. (%)  0  1 (14.3)  0 
Male sex, no. (%)  4 (50)  2 (28.6)  4 (50) 
BMI, median (IQR)  24.2 (21.2–31.3)  19.4 (17.3–22.6)  27.6(21.9–33.6) 
No. (%) with other diseases  4 (50)  7 (100)  3 (37.5)† 
Highest SOFA score, mean r SD‡  0.89 ± 0.93§  9.7 ± 5.6  10.5 ± 4.0 
SOFA score >4, no. (%)  0§  7 (100)  8 (100) 
APACHE II score, mean r SD¶  1. 6 ± 2.5§  17 ± 6.9  19.6 ± 3.8 
APACHE II score >15, no. (%)  0§  5 (71.4)  8 (100) 
Secondary bacterial infection       
 Streptococcus  pneumoniae  1 0  1 
ȕ-Streptococci, non-A, B, D  0  0  1 
 Klebsiella  pneumoniae  0 1  0 
Duration from illness onset to first medical access, d, median (IQR)  2 (1–2.2)  3 (2.5–3)  2 (2–3) 
RDT sensitivity, n/N (%)  8/8 (100) §  3/7 (42.9)  1/8 (12.5) 
Duration from illness onset to antiviral therapy, d, median (IQR)  4 (3.8–5.8)  6 (4.5–6)  6.5 (5.5–7.2) 
Duration of ICU stay, d, median (IQR)  0 (0–2)§  15 (11.5–27.5)  49.5 (22.8–56.2) 
Length of hospital stay, d, median (IQR)  5.5 (4–9.2)§  27 (21.5–54.2)  55.5 (30.2–71.2) 
28-day mortality rate, no. (%)  0  1 (14.3)  0 
Complications      
 Ventilator  dependent  0  3  3 
 Hemodialysis  0  0  1 
*ECMO, extracorporeal membrane oxygenation; BMI, body mass index; IQR, interquartile range; SOFA; Sequential Organ Failure Assessment; APACHE, 
Acute Physiology and Chronic Health Evaluation; RDT, rapid diagnostic test; ICU, intensive care unit. 
†A 49-year-old man who had a renal transplant, a 17-year-old woman with congenital heart disease, and a 64-year-old man with diabetes and 
hypertension. 
‡Range 0–24. Higher values indicate more severe disease. 
§p<0.05 for 8 patients without mechanical ventilation vs. 15 patients with mechanical ventilation with and without ECMO support. 
¶Range 0–71. Higher values indicate more severe disease. LETTERS
This report demonstrates an ap-
parently paradoxical inverse relation-
ship between a positive RDT result 
and severity of illness among patients 
with pandemic (H1N1) 2009. This 
observation cannot be explained by 
differences in the time to access to 
medical care, performance of RDT 
(7), or prior antiviral therapy. Variants 
of pandemic (H1N1) 2009 virus may 
preferentially infect the lower respira-
tory tract in certain hosts (8). Invasive 
properties of pandemic (H1N1) 2009 
virus and severity of illness may be 
more closely related to heterogeneity 
in host immunity than to viral load 
(9). US Centers for Disease Control 
and Prevention guidance advises that 
“hospitalized patients with suspected 
inﬂ   uenza should receive immediate 
empiric antiviral treatment…, a nega-
tive RIDT or DFA test result does not 
exclude inﬂ   uenza virus infection…” 
(10). Moreover, this guidance also 
recommends that collection of lower 
respiratory tract specimens may be 
useful for reverse transcription–PCR 
testing to improve diagnosis for pa-
tients suspected of having severe 
lower respiratory tract disease caused 
by pandemic (H1N1) 2009 virus. The 
current ﬁ  ndings strongly support this 
recommendation, particularly for se-
verely ill patients.
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Human Brucella 
canis Infections 
Diagnosed by 
Blood Culture
To the Editor: Brucellosis is a 
worldwide zoonosis caused by Brucel-
la spp. The 4 species known to infect 
humans are B. melitensis, B. suis, B. 
abortus, and B. canis (1). Since 1999, 
11 cases in Japan have been reported. 
Although no bacteria were isolated, se-
rum antibody detection indicated that 
4 were caused by B. melitensis or B. 
abortus acquired abroad and the other 
7 by B. canis (2). Of these 7 patients, 2 
were presumed to have received their 
infection from dogs, and the sources 
of infection for the other 5 are unclear. 
We report 2 cases of B. canis infection 
diagnosed by blood culture.
Patient 1 was a 71-year-old male 
pet shop manager with hypertension. 
He came to Chubu Rosai Hospital, 
Nagoya, Japan, on August 9, 2008, 
after having fever and fatigue for 3 
weeks, which were nonresponsive to 
third-generation cephalosporins. At 
the time of admission, his temperature 
was 37.8°C, but physical examination 
ﬁ  ndings were unremarkable. On day 
2, gram-negative coccobacilli were 
detected in a culture of blood collected 
at the time of admission. Ceftriaxone 
(1 g 1×/d) was administered, but fever 
persisted. On day 5, coccobacilli were 
growing poorly on culture media. Be-
cause the patient’s history indicated 
the possibility of a zoonotic disease, 
doxycycline (100 mg 2×/d) was ad-
ministered. Thereafter, the patient’s 
fever and generalized symptoms re-
solved. The blood specimen and iso-
lated bacteria were sent to the Na-
tional Institute of Infectious Disease, 
B. canis was identiﬁ  ed by combinato-
rial PCR (3). Serum tube agglutination 
test indicated an antibody titer against 
B. canis of 1,280 (Table). On day 10, 
streptomycin (1 g 1×/d) was added to 
the treatment regimen. On day 33, the 
patient was discharged; his laboratory 
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